INTRODUCTION
Obesity-associated insulin resistance is a hallmark of type 2 diabetes mellitus and plays a central role in metabolic syndrome (Haffner and Taegtmeyer, 2003; Olefsky and Glass, 2010; Reaven, 2005) . Many studies have shown that in obesity, there is an increased accumulation of macrophages in adipose tissue (Weisberg et al., 2003; Xu et al., 2003) , liver (Lanthier et al., 2010) , and muscle (Pillon et al., 2013) , especially pro-inflammatory M-1-like Cd11c+ macrophages that account for the majority of this increase (Lackey and Olefsky, 2016; Li et al., 2010) . Our previous studies clearly show that in vivo deletion of Cd11c+ cells improved obesity-induced insulin resistance, indicating that the chronic tissue inflammatory state plays a key causal role in obesity-induced insulin resistance (Patsouris et al., 2008) .
Chronic tissue inflammation leads to increased levels of proinflammatory cytokines, such as TNFa and IL1b, which impair insulin signaling and induce insulin resistance (Hotamisligil et al., 1996; Jager et al., 2007) . However, therapeutic efforts focusing on inhibition of TNFa or IL1b to ameliorate inflammation-induced insulin resistance have had limited success in clinical studies (Donath et al., 2013; Larsen et al., 2007; Stanley et al., 2011) . Thus, we hypothesize that there are other secreted factors which play a role in inflammation-induced decreased insulin sensitivity. Galectin-3 (also known as Mac-2), a 30 kDa lectin, contains a carbohydrate-recognition binding domain that binds to b-galactoside (Barondes et al., 1994a; Yang et al., 2008) and is localized in the nucleus, cytoplasm, and extracellular membrane. Galectin-3 (Gal3) plays an important disease-exacerbating role in autoimmune/inflammatory and malignant diseases (Gao et al., 2013; Li et al., 2014; Liu and Rabinovich, 2010) . Our previous reports found that, after switching obese mice from a high fat diet (HFD) to normal chow (NC), adipose tissue Cd11c+ macrophages express much lower levels of Gal3 compared to HFD fed mice. At the same time, there was amelioration of inflammation and insulin resistance in these diet-switched mice, despite retaining the same number of adipose tissue Cd11c+ macrophages . Therefore, we hypothesize that Gal3 can promote insulin resistance, providing a link between inflammation and decreased insulin sensitivity.
Here, we report that Gal3 KO (knockout) mice were protected from inflammation and insulin resistance and a selective small molecule Gal3 inhibitor reduces insulin resistance. Moreover, we found that in vivo Gal3 administration causes glucose intolerance and insulin resistance, whereas in vitro treatment can directly induce decreased insulin sensitivity in myocytes, hepatocytes, and adipocytes. Together these findings suggest that hematopoietic cell-derived Gal3 might be a valuable drug target for the treatment of insulin resistance.
RESULTS
Metabolic Studies in WT, Gal3 À/À, and Gal3 ± Mice In obesity, proinflammatory macrophages accumulate in adipose tissue, liver, and muscle, promoting a chronic inflammatory state, which contributes to insulin resistance. Since Gal3 is an abundant macrophage secretory factor (Liu et al., 1995; Sato and Hughes, 1994) , we assessed glucose homeostasis and insulin sensitivity in chow and HFD-fed wild-type (WT), Gal3 ± (Gal3 HET), and Gal3 À/À (Gal3 KO) mice. Body weight and oral glucose tolerance tests (OGTTs) were comparable between the WT and Gal3 KO mice on chow diet (Figures S1A and S1B). Upon HFD feeding, WT and Gal3 KO mice gained the same amount of weight ( Figure 1A) ; however, the Gal3 KO mice were much more glucose tolerant with lower blood insulin levels compared with WT mice (Figures 1B and 1C ). The glucoselowering effect of injected insulin was also greater in KO mice ( Figure 1D ), indicating improved systemic insulin sensitivity as a result of the Gal3 deletion. To measure tissue-specific insulin sensitivity, hyperinsulinemic/euglycemic clamp studies were performed. As shown in Figures 1E-1I , the amount of exogenous glucose required to maintain euglycemia (glucose infusion rate, GIR) and the glucose disposal rate (GDR) was substantially higher in the HFD Gal3 KO compared to HFD WT mice (Figures 1E and 1F) . The insulin-stimulated glucose disposal rate (IS-GDR), which primarily reflects skeletal muscle insulin sensitivity, and the ability of insulin to suppress hepatic glucose production (HGP), which reflects hepatic insulin sensitivity, was also improved in the Gal3 KO mice ( Figures 1G-1I ). Thus, Gal3 deletion led to greater in vivo insulin sensitivity in muscle and liver.
Since endogenous Gal3 circulates at relatively high levels in normal mice and humans, we asked whether heterozygous depletion of Gal3 would improve insulin resistance. To test this (E-I) (E) Glucose infusion rate (GIR) during hyperinsulinemic, euglycemic glucose clamp studies, (F) glucose disposal rate (GDR), (G) insulin-stimulated glucose disposal rate (IS-GDR), (H) hepatic glucose production (HGP), and (I) HGP suppression during hyperinsulinemic euglycemic clamp studies in WT and Gal3 KO mice on HFD.
(J) Blood Gal3 levels in WT, Gal3 HET, and Gal3 KO mice on HFD.
(K-N) Body weight of WT and Gal3 HET mice on 10 weeks HFD, (L) insulin tolerance tests (0.45 U/kg), (M) glucose tolerance tests, and (N) insulin levels during glucose tolerance tests in WT and Gal3 HET mice on HFD. Values are expressed as mean ± SEM n = 8-10 in each group, *p < 0.05, **p < 0.01 for KO versus WT (B-J), or HET versus WT (J-N). See also Figures S1 and S2.
idea, HFD Gal3+/À (Gal3 HET) mice were studied. As expected, circulating Gal3 levels are 50% lower compared to HFD WT mice ( Figure 1J) , with values down to the normal concentrations seen in lean, chow-fed mice ( Figure 2A ). Consistent with the results in the Gal3 KO mice, Gal3 het mice gained the same amount of weight as WT on HFD ( Figure 1K ) but were insulin sensitive and glucose tolerant with lower blood insulin levels ( Figures 1L-1N ). This indicates that $50% deletion of Gal3 is adequate to induce a robust improvement in glucose tolerance and systemic insulin sensitivity. We also assessed tissue insulin signaling in these mice and, as seen in Figures S1C-S1E, we observed an increase in insulin-stimulated AKT phosphorylation in adipose tissue, liver, and muscle in the Gal3 HETs compared to WT.
We found that, as chow-fed mice age, blood levels of Gal3 increase ( Figure S1F ). Interestingly, in these older chow-fed mice, Gal3 KO led to an improvement in glucose tolerance and insulin sensitivity (Figures S1G-S1I), unlike the results in young insulinsensitive mice ( Figure S1B ), but similar to the results in the HFD mice ( Figures 1B and 1D ). In general, the degree of improvement was quite robust (40%-50%) and was similar in magnitude across the HFD Gal3 KOs, HFD Gal3 HETs, and older Gal3 KO mice.
Interestingly, whereas HFD-induced obesity can lead to hepatosteatosis (Birkenfeld and Shulman, 2014; Samuel et al., 2004) , we found that deletion of Gal3 did not alter the hepatic lipid profile in HFD mice ( Figures S2A-S2G) . Table S1 .
Circulating Levels of Gal3 are Higher in Obese Mice and Humans
Since obesity is associated with macrophage accumulation in metabolic tissues and macrophages produce and secrete Gal3 (Liu et al., 1995; Sato and Hughes, 1994) , it seemed probable that blood Gal3 levels are elevated in obesity. To test this hypothesis, we measured circulating Gal3 by ELISA and found that Gal3 levels were nearly three times as high in HFD mice compared to lean age-matched chow-fed mice ( Figure 2A ). In vivo administration of clodronate to mice is an established method to deplete macrophages, and previous studies have shown that clodronate treatment leads to a marked decrease in systemic inflammation along with an increase in glucose tolerance and insulin sensitivity (Feng et al., 2011; Li et al., 2015) . Interestingly, in clodronatetreated mice, there was a marked decrease in circulating Gal3 levels, reducing these values from the elevated concentrations seen in HFD mice down to the normal levels seen in chow-fed mice ( Figure 2B ). These results suggest that macrophages may account for the majority of the increase in Gal3 levels seen in obesity.
With respect to human studies, obese subjects display significantly higher Gal3 levels than lean subjects ( Figure 2C ). Furthermore, Gal3 levels are positively correlated to both BMI and HOMA-IR (an index of insulin resistance [ Figures  2D and 2E] ), suggestive for a role in insulin resistance in man.
Gal3 and Macrophage Migration
It has been reported that Gal3 produces chemotactic effects on immune cells (Sano et al., 2000) , and consistent with this, we found that Gal3 stimulated in vitro chemotaxis of mouse intraperitoneal macrophages (IP-Macs) in a dose-dependent manner ( Figure 2F ). MCP-1-containing media (100 ng/ml) can also induce migration of WT IP-Macs ( Figure S3A ). Interestingly, loss of Gal3 does not significantly alter the ability of MCP1 to induce chemotaxis ( Figure S3A ). With respect to another macrophage function, in vitro phagocytosis was reduced in the Gal3 HET macrophages and was further reduced in the Gal3 KO cells ( Figure S3B ).
To determine if these in vitro chemotaxis results translated to the in vivo situation, we directly measured macrophage migration into adipose tissue using an in vivo macrophage tracking technique. With this approach, circulating monocytes were obtained from WT donor mice and labeled with fluorescent PKH26 dye ex vivo. The labeled monocytes were then injected into recipient HFD-fed WT or Gal3 KO mice. We found a substantially lower number of labeled macrophages in adipose tissue and liver in Gal3 KO mice ( Figure 2G ). We also conducted FACS analysis of epididymal adipose tissue (Epi-WAT) stromal vascular cells (SVCs) prepared from HFD WT and Gal3 KO mice. The results showed a lower total number of adipose tissue macrophages (ATMs) as well as $70% fewer proinflammatory CD11c-positive macrophages in Gal3 KO Epi-WAT ( Figures 2H, 2I, and S4 ). This indicates a reduced inflammatory state, and fully consistent with this idea, we found decreased expression of a variety of proinflammatory genes in adipose tissue from Gal3 KOs compared to WT ( Figure 2J and Table S1 ).
Gal3 Directly Induces Cellular Insulin Resistance
Given that circulating Gal3 levels are elevated in obesity (Figure 2A) , we asked whether Gal3 could directly act on insulin target tissues in an endocrine manner to impair insulin signaling. To assess this, we studied the effects of Gal3 treatment on L6 myocytes, 3T3-L1 adipocytes, and primary hepatocytes. Gal3 treatment inhibited insulin-stimulated glucose transport in a dose-responsive manner in L6 myocytes and 3T3-L1 adipocytes ( Figures 3A and 3B ). The same effect was observed after longer (48 hr) Gal3 treatment ( Figure S5A ). To indicate the relevancy of these findings to human biology, we conducted in vitro Gal3 treatment studies in human inducible pluripotent stem cell (iPSC)-derived skeletal muscle cells. Insulin induced a $2-fold increase in glucose transport in iPSC-derived myocytes, and this effect was blocked by Gal3 in a dose-dependent manner ( Figure S5B ). In WT primary hepatocytes, glucagon stimulates hepatic glucose output (HGO) and this increase was completely inhibited by insulin ( Figure 3C ). Gal3 alone also stimulated HGO, and as expected, this effect was not inhibited by insulin (Figure 3C, 3rd set of bars). Combination treatment with Gal3 and glucagon had the same stimulatory effect on HGO as glucagon alone, and importantly, Gal3 blocked the effect of insulin to inhibit glucagon-stimulated HGO ( Figure 3C , 4 th set of bars).
Taken together, these results indicate that Gal3 can directly induce cellular insulin resistance in the three major insulin target tissues. Gal3 can interact with glycosylated proteins through its C-terminal domain, termed the carbohydrate recognition domain (CRD), whereas full-length Gal3 forms oligomers through the N-terminal domain ( Figure S5C ) (Ahmad et al., 2004; Barondes et al., 1994b) . To determine if the CRD-Gal3 has the same effect as full-length Gal3, L6 myocytes were treated with CRD-Gal3, followed by measurement of insulin-stimulated glucose uptake. As shown in Figure 3D , the CRD-Gal3 inhibits glucose uptake similar to full-length Gal3.
To determine if these in vitro results translated to the in vivo situation, we directly injected lean insulin-sensitive chow-fed mice with recombinant Gal3. In these studies, we injected a dose of Gal3 (0.2 mg/kg) designed to raise the circulating levels from the normal values observed in lean chow mice up to the elevated values seen in HFD WT mice as shown in Figure 3E . Consistent with the in vitro data, GTTs performed 1 hr after injection showed that these mice became glucose intolerant, with a 45% reduction in area under the curve (AUC) ( Figure 3F ). In addition, these treated mice exhibit hyperinsulinemia ( Figure 3G ) and a marked decrease in insulin sensitivity as shown by a 55% increase in AUC during ITTs ( Figure 3H ). We also overexpressed Gal3 in chow-fed mice by IV administration of an adenovirus encoding the Gal3 gene (Ad-Gal3). Ad-Gal3 leads to increased Gal3 levels, producing glucose intolerance (60% increase in AUC; Figure 3I ), insulin intolerance (62% increase in AUC; Figure 3J ), and hyperinsulinemia ( Figure 3K ), showing that Gal3 can directly induce insulin resistance in vivo. It is important to note that LPS could not be detected in our recombinant Gal3 preparations ( Figure S5D ). Despite this, we took the extra step of detoxifying the Gal3 (Figure S5D) , and as expected, LPS was not detected in this material compared to the Gal3 preparation that had been spiked with LPS at a concentration of 0.5 pg/ml.
Given that IP-MACs and other monocytes or macrophages can secrete Gal3 (Figures S5E and S5F) and that Gal3 inhibited insulin action, it seems possible that macrophages can directly affect insulin action through Gal3. To access this, we isolated conditioned medium (CM) either from WT or KO IP-MACs, followed by glucose uptake assays in L6 myocytes. As shown in Figure 3L , CM from WT IP-MACs significantly blocked insulinstimulated glucose uptake compared to control medium. Importantly, the CM from KO IP-MACs had no effect to inhibit insulin action in L6 myocytes. 
Mechanisms of Gal3-Induced Cellular Insulin
Resistance Insulin binds to the insulin receptor (IR), stimulating IR tyrosine auto phosphorylation and kinase activity, leading to phosphorylation and recruitment of substrate adaptors such as insulin receptor substrate (IRS1). IRS1 then stimulates P13 kinase and PDK1, which signal downstream to AKT and glucose transport. We used L6 myocytes and 3T3-L1 cells to assess the effects of Gal3 on these events. As seen in Figures 4A and 4B, Gal3 treatment inhibits insulin-stimulated IR tyrosine phosphorylation in both cell types. There was a corresponding decrease in IRS1 tyrosine phosphorylation, as measured both by ELISA assay and western blotting in L6 myocytes and 3T3-L1 adipocytes . Consistent with these results, Gal3 treatment inhibited the effects of insulin to stimulate PDK1 (Figures 4G and S6A) and AKT (Figures 4H and S6B) phosphorylation in a doseresponsive manner in both cell types. In myocytes and adipocytes, insulin stimulation leads to GLUT4 translocation with subsequent increased glucose uptake. GLUT4 translocation was measured using the plasma membrane sheet assay ( Figure 4I ) and immunofluorescence detection of GLUT4 recruitment to the cell surface using the GLUT4 ring assay ( Figure 4J ), as previously described (Imamura et al., 1999; Vollenweider et al., 1997) . Both of these measurements show that Gal3 treatment reduces insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes (Figures 4I and 4J) . In aggregate, these data indicate that Gal3 impairs all the major steps in the insulin signaling pathway. Most likely this is due to a direct inhibitory effect of Gal3 on the IR. Consistent with this, Figure 5 shows that, when L6 cells and 3T3-L1 adipocytes are treated with Gal3, IR/Gal3 complexes can be co-precipitated from these cells. To evaluate Gal3 binding to the IR and IR phosphorylation, L6 myocytes were treated with biotinylated Gal3 (Bio-Gal3). As seen in Figure 5A , Bio-Gal3/IR complexes can be co-precipitated from these cells. In contrast, Gal3/IRS1 co-immunoprecipitated complexes were not detected ( Figure 5A ). Interestingly, the amount of IR co-precipitated with Gal3 was increased in the presence of insulin, suggesting that the binding of insulin to its receptor renders the IR/ Gal3 interaction more efficient ( Figure 5A ). Furthermore, when similar experiments were performed at 16 C (to limit any IR internalization), the same results were seen with respect to Gal3/ IR binding ( Figure 5B ). In the reverse experiment in which BioGal3 was captured followed by immunoblotting of IR, comparable Gal3/IR binding was also detected ( Figure 5C ). In control studies, we also show that, Bio-Gal3 can impair insulin-stimulated glucose uptake in L6 cells ( Figure 5D ), similar to WT Gal3. To evaluate whether Gal3 treatment affects binding of insulin to its receptor, we performed insulin binding assays in both 3T3-L1 adipocytes and primary hepatocytes. As seen in Figures  5E and 5F, Gal3 treatment did not affect insulin binding, suggesting that Gal3 interacts with the insulin receptor at a different site than insulin.
Studies in Chimeric Gal3À/À Mice Since Gal3 is secreted by macrophages in vitro (Liu et al., 1995; Sato and Hughes, 1994) , we determined the contribution of immune cells to the circulating Gal3 pool by performing bone marrow transplantation (BMT) experiments. With this adoptive transfer approach, we generated chimeric mice in which WT mice received bone marrow from either WT mice (BMT Gal3) or Gal3 KO mice (BMT Gal3 KO). As shown in Figure 6A , blood Gal3 levels were decreased by $90% in BMT Gal3 KO mice, indicating that most of the circulating Gal3 is derived from immune cells. The BMT Gal3 and BMT Gal3 KO mice gained the same about of weight on HFD ( Figure 6B ). However, the BMT Gal3 KO mice were more glucose tolerant and insulin sensitive with lower insulin levels compared to BMT Gal3 mice ( Figures  6C-6E ). Moreover, hyperinsulinemic euglycemic glucose clamp studies showed higher GIR and IS-GDR, lower HGP after insulin infusion, and elevated HGP suppression ( Figures 6F-6I ) in BMT Gal3 KO versus BMT Gal3 animals. Taken together, these results indicate that immune cells are the major contributor to systemic Gal3 concentrations in mice and that circulating Gal3 induces systemic insulin resistance.
Gal3 Inhibition Improves Insulin Sensitivity
The above studies clearly show that Gal3 can directly induce cellular insulin resistance in vitro and systemic in vivo insulin resistance and that genetic Gal3 loss of function improves insulin sensitivity. To further define the role of Gal3 and assess its potential translational implications, we turned to a pharmacologic lossof-function approach. Thus, we treated L6 myocytes with the Gal3 inhibitor compound 47 (Cpd47; Salameh et al., 2010) and found that it blocked the inhibitory effect of both full-length Gal3 and CRD-Gal3 on insulin-stimulated glucose transport (Figures 7A and 7B) . The Gal3 inhibitor also blocked the effect of Gal3 to inhibit the repressive effects of insulin on HGO in primary hepatocytes ( Figures 7C and 7D ). To extend these observations to the in vivo situation, obese HFD mice were treated with a single dose (50 mg/kg) of Cpd47 and OGTTs were performed 1 hr later. As Figure 7E shows, the Gal3 inhibitor improved glucose tolerance in these mice. To evaluate the effects of this inhibitor in the more chronic setting and at lower doses, we administered Cpd47 to HFD mice via an osmotic minipump at a dose of 6.4 mg/kg per day for two weeks. In agreement with the acute treatment data, chronic treatment also improved glucose tolerance in HFD/obese mice ( Figure 7F ).
DISCUSSION
Here, we show that circulating Gal3 levels are elevated in obese mice and humans and that Gal3 is a macrophage-derived factor that can cause in vivo systemic insulin resistance both acutely and chronically. In addition, Gal3 treatment in vitro causes decreased insulin action in adipocytes, muscle cells, and hepatocytes by inhibiting insulin receptor activity, leading to decreased downstream signaling to the insulin action cascade. Gal3 also promotes adipose tissue inflammation by inducing macrophage chemotaxis and the accumulation of proinflammatory ATMs in obesity. Thus, these studies show that bonemarrow-derived cells, such as macrophages, can secrete Gal3, which enters the circulation and can cause cellular and systemic insulin resistance. In this way, Gal3 is identified as an etiologic factor which contributes to obesity-induced insulin resistance and chronic tissue inflammation. A major piece of evidence for this new role of Gal3 in insulin resistance comes from our KO mouse studies. Here, we find that deletion of Gal3 leads to improved glucose tolerance with enhanced in vivo insulin sensitivity ( Figures 1B-1D ) in HFD Gal3 KO mice. Using hyperinsulinemic euglycemic clamp studies, this increased insulin sensitivity is expressed in both muscle and liver ( Figures 1E-1I ). This insulin-sensitive phenotype was not limited to homozygous KOs, since heterozygous Gal3 deletion, which reduces Gal3 levels in Gal3 HETs down to values observed in lean mice, also causes greater glucose tolerance and insulin sensitivity ( Figures 1L-1N ), indicating that a full reduction in circulating Gal3 levels is not necessary to observe this phenotype. Interestingly, the insulin sensitization induced by Gal3 deficiency is not restricted to the context of obesity and HFD, since older chow-fed mice with higher blood Gal3 levels also display improved glucose tolerance upon Gal3 KO ( Figures S1H and S1I) .
Deletion of Gal3 from the bone marrow compartment by transplanting Gal3 KO bone marrow into irradiated WT mice also produced a state of improved insulin sensitivity and glucose tolerance ( Figures 6C-6I) . Importantly, these studies demonstrated a >90% reduction in circulating Gal3 levels in BMT Gal3 KO mice ( Figure 6A ), indicating that BM-derived cells are the dominant source of this circulating factor. As reported previously, Gal3 is poorly expressed in mouse lymphocytes and neutrophils (Joo et al., 2001; Sato et al., 2002) , and this strengthens our conclusion that macrophages are a major source of the secreted circulating Gal3. Consistent with this, ATM Gal3 content increases on HFD and decreases on chow diet, parallel to the changes in blood Gal3 levels. With respect to the source of circulating Gal3, when we administered clodronate to WT HFD mice, we were able to achieve $80% depletion of ATMs, and this corresponded to a decrease in circulating Gal3 levels from the elevated concentration seen in HFD mice down to the normal concentrations seen in lean mice ( Figure S3A ). This suggests that a sizable component of the obesity-induced elevation of circulating Gal3 can be derived from clodronate-sensitive macrophages.
In addition to deletion of Gal3, we carried out Gal3 treatment studies. These experiments were conducted either by injecting exogenous Gal3 into WT animals or by using an adeno-Gal3 to generate Gal3 transgenic mice. Both methods of Gal3 administration led to glucose intolerance and insulin resistance ( Figures  3F-3K ), fully consistent with the phenotype observed with Gal3 deletion (Figure 1 ). In our Gal3 treatment studies, we used a dose of Gal3 designed to raise the circulating values from the normal concentration seen in lean chow-fed mice to the elevated levels observed in obese HFD mice ( Figure 3E ). Elevating the Gal3 levels to the pathophysiologic obese concentrations in these lean mice led to a marked deterioration of glucose tolerance and insulin sensitivity (Figures 3F-3H) . Lastly, we supple- 7E and 7F), consistent with the results in the Gal3 KO mice. The Gal3 inhibitor also reversed the effects of Gal3 to cause cellular insulin resistance in vitro ( Figures 7A-7D ). The concomitant improvement in insulin sensitivity and inflammatory status in the Gal3 KO and Gal3-inhibitor-treated mice fits quite well with the known interaction between obesity-induced chronic inflammation and insulin resistance. In the current case, our data show that Gal3 can directly cause decreased insulin sensitivity in the three major insulin target tissues: adipocytes, muscle, and liver. As such, these findings amplify the underlying mechanisms connecting inflammation and insulin resistance. Although the contribution of chronic inflammation to insulin resistance is reasonably well established, therapeutic attempts to correct this have not had adequate success in clinical studies. Based on our findings with Gal3, one can raise the possibility that previous therapeutic attempts to ameliorate inflammation-induced insulin resistance and hyperglycemia have not been properly directed at the underlying mechanism. These studies indicate that inhibition of Gal3 could be a future approach to the treatment of insulin resistance.
Given the magnitude of the effects of Gal3, we conducted detailed in vitro studies to elucidate the mechanisms of Gal3-induced insulin resistance. Our studies showed that Gal3 treatment led to decreased insulin signaling in adipocytes and myocytes (Figures 4 and 5) . In 3T3-L1 adipocytes and L6 myocytes, Gal3 treatment inhibited insulin-stimulated glucose transport and GLUT4 translocation in a dose-responsive manner ( Figures  3A, 3B , 4I, and 4J). In hepatocytes, Gal3 blocked the effects of insulin to suppress glucagon-stimulated hepatic glucose production ( Figure 3C ). With respect to more in-depth mechanisms, we found that Gal3 treatment led to decreased insulin-stimulated IR tyrosine phosphorylation in myocytes and adipocytes ( Figures  4A and 4B) . All of the subsequent steps in insulin signaling, such as IRS1 tyrosine phosphorylation, PDK1 activation, and AKT phosphorylation, were also inhibited by Gal3 ( Figures 4C-4H , S6A, and S6B). From these studies, we conclude that the major mechanism of action of Gal3 is to interact with the cell surface IR, inhibiting its function. This conclusion is strongly supported by our co-immunoprecipitation experiments that show a strong direct interaction between Gal3 and IR ( Figures 5A-5C ). Interestingly, the interaction of Gal3 with the IR did not inhibit insulin binding. This suggests that Gal3 and insulin bind to different sites on the IR and that Gal3 inhibits IR autophosphorylation by interfering with signal transmission from the IRa to b subunits. Based on these studies, we suggest that extracellular Gal3 can interact with the glycosylated cell surface IR, through the Gal3 CRD, leading to inhibition of IR tyrosine phosphorylation and downstream signaling, which causes insulin resistance. What other surface proteins Gal3 might bind to is not currently known. Interestingly, the interaction between Gal3 and IR can be shown in the absence of insulin but is increased in insulin-stimulated cells. This raises the possibility that insulin binding to the IR introduces a conformational change favoring Gal3 association and that the interaction of Gal3 with the IR interferes with ligand-induced IR autophosphorylation.
In addition to directly causing decreased insulin signaling, Gal3 also promotes adipose tissue inflammation. This is exemplified by the in vitro effects of Gal3 to promote macrophage chemotaxis ( Figure 2E ). This concept is reinforced by the in vivo monocyte tracking studies, showing that migration of fluorescently labeled WT donor macrophages into adipose tissue and liver in Gal3 KO recipient mice is markedly reduced compared to WT recipients ( Figure 2G ). This result is fully consistent with the decreased ATM content in HFD/obese Gal3 KO mice compared to HFD WT mice and to the decreased expression of inflammatory markers in adipose tissue in the KOs ( Figures  2I and 2K ). Previous studies have examined the effects of Gal3 KO on various aspects of atherosclerosis, glomerulopathy, hepatic steatosis, and obesity, but the current report is the first to provide an in-depth study of Gal3 on insulin action, insulin resistance, and diabetes. With respect to metabolic aspects, these earlier studies provide conflicting results without clear conclusions in common among them. For example, Pejnovic et al. (2013) reported that Gal3 KO leads to an obese phenotype on HFD, although they did not measure metabolic effects. However, in these studies, their WT mice did not gain weight on HFD diet, and this is rather inexplicable, since long-term 60% HFD causes obesity in male WT mice. In contrast, their Gal3 KO mice gained $5 g body weight over 18 weeks of 60% HFD. In our experience, male C57BL/6 mice always gain substantial weight after 18 weeks on 60% HFD, usually reaching body weights between 45-50 g. Thus, even the 35 g Gal3 KO mice reported by Pejnovic et al. (2013) would be considered remarkably lean compared to most reports. Therefore, the ''obese'' phenotype of their Gal3 KOs is only in comparison to the lean WT mice, which failed to gain weight on HFD. Pang et al. (2013) studied a different strain of Gal3 KO mice and also reported a modest degree of obesity in the KOs compared to WT. However, in this case, the weight gain in both groups was also substantially less than one usually sees after 12 weeks upon 60% HFD in male C57BL/6 mice, with final body weights of about 38 g compared to 45-50 g. These investigators reported that the Gal3 KOs displayed glucose intolerance, but also found that systemic antibiotic treatment, which normally improves glucose tolerance, as it did in their WT animals, had no effect on the KOs. Based on this, they attributed their phenotype, at least in part, to unspecified changes in the gut microbiome. Darrow and Shohet (2015) showed increased glucose levels in Gal3 KOs compared to WT on HFD. However, there was no significant difference in the basal glucose levels in the same experiment. Moreover, there were no differences in insulin sensitivity between the groups, and plasma insulin levels were lower in the Gal3 KOs, suggesting beta cell dysfunction as a cause of hyperglycemia. We did not detect evidence for beta cell dysfunction in our studies, nor was this reported in earlier papers using these mice. Baek et al. (2015) , using the same strain of Gal3 KO mice as we have used, reported a lean phenotype in the Gal3 KOs on HFD, opposite from the first two papers mentioned above. This was associated with reduced inflammation and improved metabolism, as in our studies. There are two additional papers reporting results on female Gal3 KO mice (Iacobini et al., 2009 (Iacobini et al., , 2011 . These papers are focused on either NASH or atherosclerosis, with one showing that the Gal3 KO mice were more susceptible to HFD-induced NASH, whereas the other showed that the KO mice were partially protected from atherosclerosis. Both papers found that WT and KO mice gained the same amount of weight on HFD, and most relevant to the current studies, both papers also showed that, on HFD, the Gal3 KO mice had better glucose tolerance compared to WT. Although we cannot reconcile all of the conflicting data of the above-mentioned reports, we recognize that technical differences, breeding and housing changes, and microbiome differences could all contribute. However, we believe that the results reported in the current studies are quite comprehensive with multiple different measures indicating metabolic improvement in Gal3 KOs. This concept is supported by our findings of metabolic deterioration with Gal3 treatment or overexpression and metabolic benefit with administration of a Gal3 inhibitor.
Our current studies report a marked improvement in obesityassociated inflammation, glucose tolerance, and systemic insulin sensitivity in the Gal3 KOs on HFD, as well as in aged lean 8-month-old chow-diet-fed animals (Figures 1 and S1) . Importantly, we consistently observed no differences in body weight gain between WT and Gal3 KO mice on either HFD or chow diet over many different cohorts. We also demonstrated direct in vitro effects of Gal3 to decrease insulin signaling in adipocytes, hepatocytes, and myocytes and provided a cellular mechanism for this effect. Finally, we were able to reproduce the metabolic phenotype by BMT studies with Gal3 KO donor bone marrow, indicating that BM-derived immune cells are largely responsible for the phenotype. Together, our studies are fairly comprehensive, including both genetic and pharmacologic loss-and gainof-function studies, all providing internally consistent results. Overall, we conclude that Gal3 is a hematopoietic cell-secreted factor that can directly cause decreased insulin signaling and insulin resistance and, at the same time, promote adipose tissue inflammation. This suggests the idea that inhibition of Gal3 could be an anti-diabetic therapeutic avenue to achieve improved insulin sensitivity and glucose tolerance.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Insulin in glucose uptake and hepatic glucose production assays
Sigma-Aldrich Cat#I9278
Galectin 3 protein R&D Cat#1197-GA-050 
EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Gal3À/À mice were kindly provided by Dr. Fu Tong Liu from University of California Davis. The Gal3+/À mice were acquired by breeding Gal3À/À with WT C57BL/6J mice. WT, HET and KO littermates were produced by crossing HET mice together. Animals were housed in an animal facility on a 12 h/12 hr light/dark cycle with free access to food and water. All animal procedures were in accordance with UC San Diego and Institutional Animal Care and Use Committee-approved protocols, and conformed to the Guide for Care and Use of Laboratory Animals of the NIH. Eight week old mice male WT (C57BL6/J), Gal3À/À and Gal3+/À mice (n = 10 each group) were fed with high fat diet (HFD, 60% kcal from fat; D12492, Research Diets) for 8 weeks. Gal3 inhibitor was administered by a mini-pump (Alzet), which was implanted subcutaneously in HFD fed mice. Plasma insulin was measured with ELISA kits from ALPCO. Plasma FFA levels were measured enzymatically using a kit from WAKO Chemicals. Plasma Gal3 levels were measured by ELISA. Phospho-IRS was measured by ELISA.
Clinical Samples
Human Gal3 studies were conducted using archival plasma samples and measurements of BMI, type 2 diabetes status, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) from 52 non-diabetic (n = 27) and type 2 diabetic (n = 25) human subjects with a broad range of BMI (18.4-50.9 kg/m2). Human Gal3 levels in plasma isolated from blood collected in EDTA tubes was measured using a kit from Calbiochem. The subject cohort includes subjects from three clinical studies. The experimental protocol for each study was approved by the Institutional Review Board for Human Subjects of the University of California, San Diego. As described previously (Sears et al., 2009 ), all subjects were volunteers, generally healthy with normal liver and kidney function. Exclusion criteria were active cardiac, liver, or renal disease or long-term complications from diabetes. None of the nondiabetic subjects were taking medications that alter glucose tolerance. Diabetic subjects taking anti-diabetes medications (sulfonylurea or metformin) were asked to discontinue their medications for at least two weeks prior to participation.
Cell Lines and Primary Hepatocytes L6 rat skeletal myoblasts were cultured in a-MEM with 10% FBS and antibiotics. After cultures reached 80%-90% confluency, medium was switched to 2% FBS to allow differentiation and myotube formation. After 8-10 days, cultures were used for experiments.
Primary hepatocytes isolation published was performed according to methods published by Zhong L (Zhong et al., 2016) . Briefly, Buffer A (Calcium and magnesium-free PBS containing 0.2 mM EGTA, 10 mM HEPES, 1 mM glucose and 0.2% BSA) and Buffer B (PBS with 1 mM magnesium and 1 mM calcium, 0.2% BSA, and 30 mM HEPES) containing collagenase (40 ug/ml) were aliquoted into 50 mL tubes and kept warm at 40 C in a water bath. KCl concentration in Buffer A and B was adjusted to 5 mM. Mice were anaesthetized by intramuscular injection of an anesthesia cocktail (Ketamine, Xylazine, Acepromazine cocktail). Hepatocytes were prepared by collagenase digestion via catheterization of the inferior vena cava (IVC) using a 24G needle catheter. Prior to collagenase infusion, the liver was perfused (3-4 min) with Buffer A via IVC after severing the portal vein. The color of the liver was observed, which changed to a beige or light brown color. Next, perfusion was continued with collagenase in Buffer B for 2 min. Within 2 min of digestion, the liver was monitored for the appearance of cracking on the surface. Perfusion was stopped immediately and the liver was excised out into ice-chilled Buffer A. Cells from the digested livers were teased out, suspended in Buffer A, filtered through 100 mm nylon filter and centrifuged at 60 3 g for 6 min at 4 C. The cell pellet was washed once in Buffer B (without collagenase) by resuspending and centrifuging at 60 3 g for 6 min at 4 C. The cell pellet was then mixed with Percoll (adjusted to physiological ionic strength with 10 3 PBS) to a final concentration of 36% and centrifuged at 100 3 g for 10 min. Hepatocytes were collected as a pellet and washed once with Buffer B (no collagenase) and then cultured on collagen-coated plates (GIBCO, Life technologies, Carlsbad) (100.000 cells per well in 24-well plate) in Williams Medium E (Life Technologies, Carlsbad) containing penicillin and streptomycin, 10 nM dexamethasone (all from Life Technology) and 10% FBS. Plates can be incubated overnight in this medium and then switched to a serum-free medium. Alternatively, after attachment (3 hr), medium can be replaced by a serum free-medium (Williams Medium E with penicillin, streptomycin, gentamycin, and amphotericin B and 0.2% BSA without dexamethasone and serum). After 4 hr or after overnight culture in this medium, cells are ready for assay. If a pretreatment with a test compound (from 15 min to 15 hr) is needed for an experiment, it can be initiated during the switch to serum-free medium (for a 15-16 hr preincubation) or the next day (for 15 min to 3 hr) before the assay.
METHOD DETAILS
ITTs, GTTs, and hyperinsulinemic-euglycemic clamp study Male WT, Gal3À/À and Gal3+/À mice (n = 10 each group) were fed with 60% high fat diet (HFD) for 8 weeks, followed by glucose tolerance tests (GTTs), insulin tolerance tests (ITTs) and hyperinsulinemic-euglycemic clamps. For GTTs, animals were IP injected with dextrose (1 g/kg) after 6 hr of fasting, and blood was drawn to measure glucose levels at 0, 15, 30, 60, 90, and 120 min after dextrose injection. For ITTs, 0.4-0.5 units/kg of insulin was IP injected after 6 hr of fasting, and blood was drawn at 0, 15, 30, 60, 90, and 120 min after insulin injection.
Hyperinsulinemic-euglycemic clamps were performed as previously described (He et al., 2003; Li et al., 2010; Lu et al., 2010) . Only mice losing < 6% of their pre-cannulation weight after 4-5 d of recovery were used. The clamp experiments began with a constant infusion (5 mCi/h) of D-[3-3H] glucose (Du Pont-NEN) in 6-h-fasted mice. After 90 min of tracer equilibration and basal sampling, glucose (50% dextrose; Abbott) and tracer (5 mCi/h) plus insulin (6 mU/kg/min) were infused into the jugular vein. Small blood samples were drawn from the tail vein at 10 min intervals and achievement of steady-state conditions (120 mg/dl ± 5 mg/dl) was confirmed at the end of the clamp by maintaining glucose infusion and plasma glucose concentration for a minimum of 20 min. Blood samples at t = À10, 0 (basal), 110 and 120 (end of experiment) min were taken to determine glucose-specific activity and insulin concentration. Tracer-determined rates were quantified by using the Steele equation for steady-state conditions (Steele, 1959) . At steady state, the rate of glucose disappearance, or total GDR, is equal to the sum of the rate of endogenous glucose productions (HGP) plus the exogenous (cold) GIR. The IS-GDR is equal to the total GDR minus the basal glucose turnover rate.
SVCs isolation, and FACS analysis
Stromal vascular cells (SVCs) isolation and FACS analyses were performed as previously described (Lee et al., 2014; Li et al., 2010) . FACS gating results are shown in Figure S6 . Unstained, single stains and FMO (fluorescence minus one) controls were used to set compensation and gates. In addition, bead compensation was used to verify negative and positive fluorescence signals using FlowJo software. To gate out negative/positive signals for each color used, compensation beads were prepared (each fluorescence antibody + compensation beads) and data applied to the + FMO compensation in the control samples.
Immunohistochemistry
Liver was fixed in formalin, embedded in paraffin and sectioned for H&E staining.
In vitro chemotaxis assay
In vitro chemotaxis assay was performed as previously described (Oh et al., 2010) . Briefly, mouse thioglycollate-elicited peritoneal macrophages were isolated from WT, HET and KO mice. For the migration per se, 100,000 intraperitoneal macrophages (IP-Macs) were placed in the upper chamber of an 8 mm polycarbonate filter for 30 min. DMEM with Gal3 or Mcp-1 (100 ng/ml) was placed in the lower chamber. After 3 hr of migration, cells were fixed in 4% paraformaldehyde, stained with 4 0 , 6-diamidino-2-phenylindole, images taken on an Olympus MXV10 Macro-view microscope and counted using ImageJ software (NIH).
In vivo monocyte tracking Leukocyte pools from C57BL/6J WT mice, bled by retro orbital sinus, were subjected to RBC lysis buffer and monocyte subsets were enriched with EasySep mouse monocyte enrichment kit following the manufacturer's instructions. Isolated monocytes (2 3 10E6 to 5 3 10E6) were washed once in serum-free medium (RPMI-1640) and suspended in 2 mL of Diluent solution C (included in the PKH26 labeling kit). Two ml of PKH26 at 2 3 10-3 M in Diluent C was added and mixed, and the cells were incubated for 10 min at room temperature in the dark. The staining reaction was stopped by addition of an equal volume (2 ml) of medium supplemented with 10% FBS. The mixture was centrifuged and the cells were washed once and resuspended in serum-containing medium. Subsequent to labeling with PKH26, the monocytes were counted and $0.5 3 10E6 viable cells were suspended in 0.2 mL PBS and i.v. Injected retroorbitally into recipient WT and Gal3 KO mice on HFD. Five days after injection, SVCs were isolated from visceral fat tissue and analyzed by FACS.
RNA isolation and qPCR
Total RNA was extracted from adipose tissue using an RNA purification kit (QIAGEN). First-strand cDNA was synthesized using SuperScript III and random hexamers. qPCR was carried out in 25 mL reactions using iTaq SYBR Green supermix on an MJ Research Chromo4 Real-Time PCR system (Bio-Rad). Relative Gene expression was calculated as mRNA level normalized to that of a standard housekeeping gene (36B4) using the DDCT method. The specificity of the PCR amplification was verified by melting curve analysis of the final products using Opticon 3 software. Primer sequences were provided in Table S1 .
Western blot analysis L6 myocytes and 3T3-L1 adipocytes were homogenized in RIPA buffer supplemented with protease and phosphatase inhibitors. Cell lysates were subjected to western blotting. The protein bands were analyzed using densitometry and ImageJ image analysis software, normalizing phosphorylated protein to total protein bands. Arbitrary densitometry units were quantified and are expressed as mean ± SEM.
Immunoprecipitation assay L6 myocytes and 3T3-L1 adipocytes were homogenized in lysis buffer (150 mM NaCl, 50 mM HEPES (pH 7.4), 1mM EDTA, 1% NP-40, 0.2 mM PMSF, with protease and phosphatase inhibitors) and 3 mg of cell lysate protein was incubated with 4.5 mg of mouse anti-IR antibody or anti-IRS1 antibody. Presence of IR or IRS1 in the precipitates was detected by a rabbit anti-IR or IRS1 antibody. For the reverse IP experiment, a biotin protein interaction pull down kit (Thermo Fisher Scientific, #21115) was used.
rhodamine-conjugated secondary antibody (1:1000 dilution) at RT for 1 hr. Cell surface GLUT4 was evaluated for the presence of plasma membrane-associated GLUT4 staining (ring assay), or immunofluorescence was quantified (sheet assay), using a confocal microscope (AXIOVERT 100M, ZEISS, Germany). The observer was blinded to the experimental conditions.
Insulin binding experiments
The ability of insulin to compete for 125 I-insulin binding to insulin receptors on differentiated 3T3-L1 adipocytes or primary hepatocytes was performed as previously described Olefsky and Kolterman, 1981) . Briefly, 3T3-L1 adipocytes (in 24-well culture plates) were used 8 days after differentiation and primary hepatocytes (in 24-well culture plates) were used after overnight culture. The concentration of galactin-3 (Gal-3) used for treatment of cells was 250 ng/ml. BSA Cell cultures were exposed to serum-free media with 0.2% BSA for 3 hr before starting Galactin-3 treatment. After a 2 hr preincubation with saline or Gal-3 in serumfree medium at 37 C, cultures were adapted to 15-17 C. At that time, culture medium was switched to 0.3 mL HKRB buffer containing 0.2% BSA (with or without Gal-3). HKRB buffer was pre-equilibrated at 15-17 C. Insulin was prepared at different concentrations in individual tubes (4 3 0.3 mL = 1.2 mL + 0.2 mL extra = total 1.4 mL for 4 wells / insulin concentration). A fixed amount of 125 Iodinated
Insulin was then added to each insulin tube: 4 3 0.2 mCi = 0.8 mC per tube for 4 wells (0.2 mC (0.2 nM) per well). Final concentrations of insulin were 0-1.0 mM in each well and the prepared tubes were kept in ice. An aliquot (30 ml) of insulin solution from the tubes were added to designated wells representing particular insulin concentrations. This is a competition binding assay in the presence of a fixed Gal-3 concentration. Hot insulin binding will be displaced/decreased with increasing cold insulin concentrations. If Gal-3 increases or decreases the insulin binding the curve will be shifted right or left accordingly. After 2 hr' incubation, wells were washed 3 times with cold PBS. Cells were dissolved in 1 N NaOH. Aliquots were saved for protein estimation. The remaining liquids were transferred to 12 3 75 glass tubes and subjected to counting in a gamma counter. Counts of the highest insulin concentration (1 mM) were used to represent non-specific binding because binding is almost saturated at an insulin concentration of 100 nM. This non-specific count at 1 mM insulin was subtracted from each count to determine specific binding. A curve was then created by plotting insulin concentration versus specific binding.
Lipid contents measurement in the liver of Gal3À/À mice on HFD Lipids in liver were measured by Lipomics Technologies as previously described .
Clodronate treatment C57BL6/J mice were fed with 60% HFD (Diet Research) for 12 weeks from 8 week old and then treated with clodronate as previously described .
Bone marrow transplantation
Male C57BL/6J mice (3 months old) were acquired from Jackson Laboratories. To generate irradiated chimeras, mice received a lethal dose of 10 Gy radiation, followed by tail-vein injection of 3 3 10 6 bone marrow cells from WT or Gal3 KO mice. Four to 6 weeks after the BMT, mice were bled to assess white blood cell number and differential by standard techniques. Genomic DNA was extracted from the circulating blood leukocytes and genotyped by PCR to analyze reconstitution efficiency. After 6 weeks recovery on the NC diet, animals were either kept on NC (12% kcal from fat; Purina 5001, LabDiet) or fed a HFD (60% kcal from fat; D12492, Research Diets) for an additional 16 weeks.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as the means ± SEM The significance of differences between groups was evaluated using ANOVA. The p value < 0.05 was considered significant.
Statistical parameters including the exact value of n, the definition of center, dispersion, and precision measures (mean ± s.e.m) and statistical significance are reported in the Figures and the Figure Legends . Data are judged to be statistically significant when p < 0.05 by two-tailed Student's T-Test or 2-way ANOVA, where appropriate. Outliers were excluded based upon analysis by the ROUT Test with Q = 0.2% (selecting for only definitive outliers). In figures, asterisks denote statistical significance (*, p < 0.05; **, p < 0.01). Pearson correlation coefficients were calculated with PRISM and statistical significance is based upon the assumption that values exhibit a Gaussian distribution. Statistical analysis was performed in Graph Pad PRISM 6.
DATA AND SOFTWARE AVAILABILITY

Software Availability
The software is available on the web sites linked in the Key Resources Table. e6 Cell 167, 973-984.e1-e6, November 3, 2016
